Mycenax, together with Alfresa Holdings, Kidswell Bio and Chiome Bioscience, has established Alfenax Biologics, a joint venture designed to build a biologics manufacturing base in Japan with end-to-end CDMO and contract manufacturing capabilities. The agreement follows approval of an MHLW
NorthX Biologics, a CDMO and Swedish innovation hub for advanced biologics, and Mendus have announced the completion of GMP manufacturing certification for vididencel, Mendus’ lead cell therapy product. The milestone concludes a two-year collaboration initiated in 2023 to establish scalable,
Samsung Biologics has secured land for a new manufacturing campus in Songdo, Incheon, as the company prepares to expand its contract development and manufacturing (CDMO) portfolio beyond its established antibody operations. The land purchase agreement was signed with the Incheon
Grindeks Group has announced the introduction of CDMO and out-licensing services, marking a shift in its business development strategy under its new leadership. The company stated that although it has focused on its own brand portfolio over the past decade,
Piramal Pharma Solutions has announced the completion of its organisation-wide effort to comply with global requirements for nitrosamine impurities in pharmaceuticals. Nitrosamines are unintended carcinogenic byproducts, and regulatory expectations for nitrosamine drug substance-related impurities have expanded in recent years. The
medac CDMO has announced a partnership with UroGen Pharma to support the development and supply chain of UGN-103, using medac’s licensed mitomycin formulation and manufacturing services. The collaboration is aimed at advancing the candidate therapy and enabling reliable access to
eXmoor Pharma and the Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have formed a strategic collaboration to strengthen the UK’s cell and gene therapy development and manufacturing ecosystem. The agreement links CVIC’s early-phase
“The world can change overnight. We have to accept volatility as part of the world we live in.” Peter DeYoung, CEO of Piramal Global Pharma, has spent 13 years with the Piramal Group, navigating the complexities of pharmaceutical manufacturing across
As clinical development timelines compress and therapeutic complexity rises, pharmaceutical sponsors must secure manufacturing partnerships that adapt to uncertainty without draining budgets. How to structure CDMO contracts that deliver both flexibility and cost efficiency has become a strategic imperative and
Microsize has signed an agreement to acquire MicroMacinazione (Mic Mac), a dedicated micronisation facility in Monteggio, Switzerland, from Lonza. The deal follows Microsize’s acquisition of Lonza’s Quakertown, Pennsylvania site in 2022 and forms part of a broader strategy to build
